Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating NALIRIFOX and GnP in First-Line Metastatic Pancreatic Cancer
NCT07163273Phase 2Recruiting
- Sponsor
- Northwell Health
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, nanoliposomal irinotecan, oxaliplatin, gemcitabine, paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Northwell Health. Started Jun 2025; status: recruiting.
02
Drugs
fluorouracilnanoliposomal irinotecanoxaliplatingemcitabinepaclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07163273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163273.